Introduction {#sec1-1}
============

The high prevalence, mode of transmission, association with cervical cancer and availability of effective vaccines all have made Human Papillomavirus (HPV) a significant virus and of public health importance.\[[@ref1]\] Cervical cancer is the second most common type of cancer occurring in women worldwide, it has caused the death of about 275,000 women with about 529,000 new cases yearly. More than 80% of these deaths occur in developing countries, where cervical cancer is the leading cause of death in adult females.\[[@ref2][@ref3]\]

In Nigeria, cervical cancer is the most common genital tract malignancy among women. Most of which are caused by HPV. The cancer is usually preceded by a premalignant stage which can be prevented by HPV immunization when appropriate and can be cured if detected early by regular screening. Follow up of abnormal test results have also been recommended.\[[@ref4][@ref5]\] An estimate of 40.43 million women are at risk of developing cervical cancer and the number of women estimated to harbor cervical Human Papillomavirus (HPV) infection is about 23.7% with over 90% of invasive cervical cancer attributed to HPV subtypes 16 or 18, current estimates also indicates that 14,089 women are diagnosed and 8,240 die from cervical cancer.\[[@ref6][@ref7]\]

HPV 16 and HPV 18 are responsible for 70% of cervical cancer and most non-cervical HPV associated cancers. While HPV infection is the most important risk factor for cervical cancer, other predisposing factors include: early age of sexual activities, early marriage (below 20 years of age), multiple sexual partners, unprotected sex, long term use of hormonal contraceptives, increased number of pregnancies, smoking, and unhygienic practices.\[[@ref8][@ref9][@ref10]\]

HPV is one of the common sexually transmitted infections implicated in 5% of cancers globally including most cervical cancer cases. In UK, HPV vaccine has been offered routinely to girls aged 11-13 years and cervical cancer screening to women aged 25-64 years since 2008.\[[@ref11]\] HPV vaccination offers a unique opportunity for primary prevention of cervical cancer. Two HPV vaccines (Gardasil and Cervarix) protect against the two strains of HPV types 16 and 18, the vaccine is approved and recommended for use in females between 9-26 years of age, and the Advisory Committee on Immunization Practices (ACIP) recommends 'catch up vaccination' for females between 13-26 years of age.\[[@ref12]\]

A significant impact has been made on the health and well-being of the world through the different types of life-saving vaccines. There is however the need for a robust public health and primary care partnership in order to continuously achieve national immunization coverage targets and low incidence of vaccine-preventable diseases. Primary care providers detect infectious disease among patients and report same to state or local health departments. This information usually drives public health response. Public health usually works with primary care providers to ensure adequate access to vaccines and provision of healthcare services to individuals, families and the community as a whole. This collaboration and integration of public health and primary care influences and reinforces the capabilities of each entity to deliver critical services. Primary care benefits from public health\'s role in policy, population health, health equity and education, while public health benefits from primary care\'s ability to provide individual patient assessment, disease management, care coordination, and quality improvement. Most parents follow the advice of their primary health care providers and conform to the national immunization requirements.\[[@ref13]\]

HPV has remained prevalent in the United States even with the presence of a safe and effective vaccine with highest risk period in the late adolescence and early adulthood. Therefore, college students have been the target for HPV prevention and vaccination promotion particularly in regions with low vaccination rates.\[[@ref14]\] This study assessed the knowledge, attitude, uptake of Human Papillomavirus vaccine and factors influencing uptake among female undergraduates in Lagos State Polytechnic, South west Nigeria.

Subjects and Methods {#sec1-2}
====================

Study setting {#sec2-1}
-------------

The study setting was Lagos state College of Science and Technology (LASPOTECH), Nigeria which has both part and full-time students. The Polytechnic operates on three Campuses namely; Isolo, Surulere and Ikorodu which run programs in National diploma (ND) and in Higher National diploma (HND).\[[@ref15]\]

Study population, study design, sample size determination and selection of participants {#sec2-2}
---------------------------------------------------------------------------------------

The study population used were female part-time students of the LASPOTECH Isolo and Surulere, Lagos, Nigeria. This was a descriptive, cross-sectional study design. The minimum sample size was determined using Cochran\'s formula (*n* = z^2^ × *p* × q/d^2^), with a standard normal deviation at 95% confidence interval (1.96), a prevalence rate of 31.2% (proportion of female students that had a correct knowledge of HPV vaccine from a previous study),\[[@ref16]\] and the error of precision at ± 5% (0.05). The minimum sample size was 330, to adjust for none response an additional 20% was added to the minimum sample and a sample size of 396 was calculated, however a total of 400 participants were recruited for this study.

A multistage sampling method was employed to select female undergraduates (aged 15--24 years) who were students of LASPOTECH. A simple random sampling method by ballot was used to select respondents' departments in stage one as well as respondents' level at stage two. A systematic random sampling method based on sitting arrangements of the students was used to select the eligible participants at stage three.

Study instrument and data collection {#sec2-3}
------------------------------------

The survey questionnaire (semi-structured, self-administered) which was used for this study was adapted from a review of relevant literatures.\[[@ref17][@ref18][@ref19]\] The questionnaire was divided into four sections: "Section A" elicited the socio-demographic data of the respondents, "Section B" analyzed the knowledge of HPV and its vaccine while, "Section C" obtained the attitude of female undergraduates towards HPV vaccine. Furthermore, "Section D" derived the Uptake of HPV vaccine as well as the possible factors influencing uptake of the vaccine.

Statistical analyses {#sec2-4}
--------------------

Data collected was entered into and analyzed using IBM SPSS version 20 statistical package. The results were summarized into the socio-demographic characteristics, knowledge and attitude scores of study participants. Chi-square was used to determine the statistical significance of observed differences for categorical and continuous variables respectively. The statistical significance was set at *P* ≤ 0.05.

Ethical considerations {#sec2-5}
----------------------

Ethical approval for this study was obtained from the Health Research and Ethics Committee (HREC) of the Lagos University Teaching Hospital (LUTH) (Health Research Committee assigned Number: ADM/DCST/HREC/APP/267, Date of approval was 10^th^ October, 2018). A written informed consent was obtained from respondents before enrollment into the study. They were informed on the scope and objectives of the study. For confidentiality, all questionnaires were made anonymous and participation was voluntary.

Results {#sec1-3}
=======

Socio-demographic characteristics {#sec2-6}
---------------------------------

The mean age of respondents was 21.3 ± 2.0 years. Most (58.3%) of the respondents were in National Diploma level two. More than half of the respondents (56.8%) have had a previous sexual experience and 71.8% had their first sexual experience within the ages of 17-20 years. Majority (94.9%) of those who were sexually active had less than three sexual partners, 75.2% of them used condoms during sexual intercourse, while 36.4% used other forms of contraceptives \[[Table 1](#T1){ref-type="table"}\].

###### 

Socio-demographic characteristics and sexual history of the respondents

  Variables                                  Frequency *n*=384   Percentage (%)
  ------------------------------------------ ------------------- ----------------
  Age (years)                                                    
   17-19                                     79                  20.6
   20-22                                     182                 47.4
   23-25                                     123                 32.0
  Mean±SD=21.3±2.0 years                                         
  Religion                                                       
   Christian                                 230                 59.9
   Islam                                     149                 38.8
   Others                                    5                   1.3
  Ethnicity                                                      
   Yoruba                                    269                 70.1
   Hausa                                     23                  6.0
   Igbo                                      68                  17.7
   Others                                    24                  6.3
  Level of study                                                 
   National Diploma (ND)                     294                 76.5
   Higher National Diploma (HND)             90                  23.5
  Course of study                                                
   Accountancy                               99                  9.4
   Banking and finance                       36                  25.8
   Business administration                   123                 32.1
   Computer science                          29                  7.6
   Marketing                                 31                  8.1
   Mass communication                        66                  17.2
  Previous sexual experience                                     
   Yes No                                    218 166             56.8 43.2
   Age at first sexual intercourse (years)   n=218               
   \<16                                      28                  13.1
   17-20                                     153                 71.8
   21-24                                     37                  15.1
  Number of sexual partners                                      
   \<3                                       206                 94.9
   4-6                                       8                   3.7
   7-9                                       3                   1.4
  Use of condoms for sexual intercourse                          
   Yes                                       161                 75.2
   No                                        56                  26.1
  Use of other contraceptives                                    
   Yes                                       78                  36.4
   No                                        136                 63.6

Respondents' knowledge of HPV and its vaccine {#sec2-7}
---------------------------------------------

[Table 2](#T2){ref-type="table"} shows that about two-third (65.6%) of the respondents did not know the symptoms of HPV infection while 63.2% did not know the risk factors for HPV infection. More than half did not know the diseases caused by HPV (54.4%) as well as the mode of transmission (57.6%).

###### 

Respondents' knowledge of HPV infection and vaccination

  Variables                                          Frequency (*n*=384)   Percentage (%)
  -------------------------------------------------- --------------------- ----------------
  Diseases caused by HPV                                                   
   Genital warts                                     45                    11.7
   HIV                                               22                    5.7
   Oral cancer                                       24                    6.3
   Cervical cancer                                   143                   37.2
   I don't know                                      209                   54.4
  Symptoms of HPV infection                                                
   Vaginal bleeding                                  52                    13.5
   Severe headache Blood stained vaginal discharge   20 59                 5.2 15.4
                                                                           
   Pain during sexual intercourse                    59                    15.4
   I don't know                                      252                   65.6
  Mode of transmission of HPV                                              
   Faeco-oral                                        12                    3.1
   Physical                                          11                    2.9
   Sexual intercourse                                144                   37.5
   Kissing                                           21                    5.5
   I don't know                                      221                   57.6
  Risk factors for HPV infection                                           
   Early sexual debut                                65                    16.9
   Obesity                                           5                     1.3
   Smoking                                           22                    5.7
   Multiple sexual partner                           99                    25.8
   I don't know                                      239                   63.2
  Methods of preventing HPV                                                
   HPV Vaccination                                   98                    25.5
   Condom use                                        66                    17.2
   Regular HPV screening                             55                    14.3
   Abstinence                                        72                    18.8
   I don't know                                      307                   53.9
  What HPV vaccine prevent against                                         
   Cancer of cervix, vagina and vulva                146                   38.0
   Cancer of the breast                              17                    4.4
   Cancer of the anus, tongue and throat             16                    4.2
   Cancer of the Penis in men                        13                    3.4
   I don't know                                      226                   58.9
  Route of HPV vaccine administration                                      
   Through oral drops                                15                    3.9
   Tablets                                           30                    7.8
   Through injections                                66                    17.2
   Through skin patches                              19                    4.9
   I don't know                                      269                   70.1
  Recommended Doses of HPV                                                 
   1 dose                                            27                    7.0
   2-3 doses                                         63                    16.4
   \>3 doses                                         10                    2.6
   I don't know                                      280                   72.9
  Recommended age of vaccination with HPV                                  
   vaccine                                                                 
   Before first sexual intercourse                   85                    22.1
   After first sexual intercourse                    28                    7.3
   If you have more than one sexual partner          51                    13.3
   I don't know                                      245                   63.8
  Who should be vaccinated against HPV                                     
   Females                                           130                   33.9
   Males                                             7                     1.8
   Both                                              90                    23.4
   I don't know                                      155                   40.4

\*-Multiple responses allowed

Majority (72.9%) of the respondents did not know the required number of doses of HPV vaccine neither the route of vaccination (70.1%). Similarly, more than half (58.9%) of the respondents did not know the diseases prevented by HPV vaccine while about two-third (63.8%) did not know the time of vaccination. A substantial proportion (40.4%) did not know who should be vaccinated against HPV. Overall, the majority (97.0%) of the respondents had very poor knowledge of HPV and the vaccine.

Attitude of respondents towards uptake of HPV vaccine HPV vaccine {#sec2-8}
-----------------------------------------------------------------

In general, majority (92.7%) of the respondents had positive attitude towards uptake of HPV vaccine. Over two-third (69.8%) of the respondents agreed to the statement: "HPV vaccination should be included in the "National Program on Immunization", while less than a third (27.4%) agreed to the statement "HPV vaccine may have long negative effects on me" \[[Table 3](#T3){ref-type="table"}\].

###### 

Respondent's attitude towards uptake of HPV vaccination (*n*=384)

  Statements                                                                                  Disagree *n* (%)   Undecided *n* (%)   Agree *n* (%)
  ------------------------------------------------------------------------------------------- ------------------ ------------------- ---------------
  HPV vaccine is effective in preventing cervical cancer                                      19 (5.0)           100 (26.0)          265 (69.1)
  I will take the vaccine because I feel at risk of getting HPV                               72 (18.8)          122 (31.8)          190 (49.5)
  I feel the vaccine will keep me safe from cervical cancer                                   23 (6.0)           105 (27.3)          256 (66.7)
  I feel it is better to be vaccinated before becoming sexually active                        48 (12.5)          110 (28.6)          226 (58.9)
  The cost of the vaccine the vaccine discourages me from getting                             99 (25.8)          113 (29.4)          172 (44.8)
  I will use the vaccine if it is available in the clinic to students at a subsidized price   48 (12.5)          86 (22.4)           250 (65.1)
  I feel only sexually active ladies should get the vaccine                                   149 (38.8)         113 (29.4)          122 (31.8)
  HPV vaccine may have long negative effects on me                                            127 (33.1)         152 (39.6)          105 (27.4)
  More information on HPV and its vaccine will be needed before I take the vaccine            34 (8.8)           101 (26.3)          249 (64.8)
  HPV vaccination should be included on the National Program on immunization                  33 (8.6)           83 (21.6)           268 (69.8)

\*Price of one dose of HPV vaccine is about ₦8,000; three complete doses become ₦24,000. Minimum wage in Nigeria is ₦18,000

Uptake of HPV vaccine {#sec2-9}
---------------------

Only ten (2.6%) of the respondents have received HPV vaccine, out of which 60% completed the vaccine doses. However, more than half (54.8%) of the respondents were willing to be vaccinated. The three most common barriers to non-uptake of HPV vaccine mentioned include 'the need for more information' (33.4%), safety concerns (21.1%) and cost of the vaccine (17.6%) among others \[[Table 4](#T4){ref-type="table"}\].

###### 

Uptake of HPV vaccine among the respondents

  Variables                                    Frequency (*n*=384)       Percentage (%)
  -------------------------------------------- ------------------------- --------------------
  Ever received HPV vaccine? (*n*=384)                                   
   Yes                                         10                        2.6
   No                                          374                       97.4
  Completed the vaccine (*n*=10)                                         
   Yes                                         6                         60
   No                                          4                         40
  Willingness to be vaccinated (*n*=374)                                 
   YES                                         205                       54.8
   NO                                          169                       45.2
                                                                         
  **Reasons for none uptake of HPV vaccine**                             
                                                                         
  **Reasons**                                  **Frequency (*n*=169)**   **Percentage (%)**
                                                                         
  Not sexually active                          65                        17.4
  Too expensive                                66                        17.6
  Too old for the vaccine                      8                         2.1
  Already infected with HPV                    5                         1.3
  Not sure about the safety of the vaccine     81                        21.1
  Don't know where to get the vaccine from     66                        17.6
  Need more information about the vaccine      125                       33.4
  The vaccine is against my cultural belief    27                        7.2

\*Multiple responses allowed

Factors associated with knowledge and attitude towards HPV vaccination {#sec2-10}
----------------------------------------------------------------------

Statistically significant associations were found between respondent\'s age, level of study, course of study and knowledge of HPV vaccine. Similarly, previous sexual experience and use of condom were statistically significant with knowledge of HPV and vaccine. Also, previous sexual history, number of sexual partners and use of condom were statistically significant with respondents' attitude towards HPV vaccine (*P* ≤ 0.05) \[[Table 5](#T5){ref-type="table"}\].

###### 

Associated factors of knowledge and attitude towards HPV vaccination

  ------------------------------------------------------------------------------------------------------------
  Knowledge of HPV vaccine                                                             
  -------------------------------------- ---------------------- ---------------------- -----------------------
  Age group (years)                                                                    

   17-19                                 2 (2.5)                77 (97.4)              X^2^=12.746

   20-22                                 3 (1.6)                179 (98.3)             *P*=0.013

   23-24                                 6 (4.9)                117 (95.1)             

   Total                                 11 (2.9)               373 (97.1)             

  Level of study                                                                       

   ND                                    4 (1.4)                290 (98.6)             X^2^=22.428

   HND                                   7 (7.8)                83 (92.2)              *P*=\<0.001

   Total                                 11 (2.9)               373 (97.1)             

  Course of study                                                                      

   Accountancy                           4 (4.0)                95 (96.0)              

   Banking and Finance                   0 (0.0)                36 (100.0)             

   Business Administration               1 (0.5)                122 (99.5)             

   Computer Science                      0 (0.0)                29 (100.0)             

   Marketing                             4 (12.9)               27 (87.1)              

   Mass Communication                    2 (3.3)                64 (96.7)              

   Total                                 11 (2.9)               373 (97.1)             X^2^=38.672 *P*=0.003

  Previous sexual experience                                                           

   Yes                                   9 (4.1)                137 (95.9)             X^2^=7.830

   No                                    2 (1.2)                164 (98.8)             *P*=0.020

   Total                                 11 (2.9)               373 (97.1)             

  Use of condom\                         6 (3.7)\               155 (96.2)\            X^2^=8.639\
   Yes\                                  5 (2.2)\               218 (97.7)\            *P*=0.013
   No\                                   11 (2.9)               373 (97.1)             
   Total                                                                               

                                                                                       

  **Attitude towards HPV vaccination**                                                 

                                                                                       

                                         **Positive *n* (%)**   **Negative *n* (%)**   **Statistical tests**

                                                                                       

  Previous sexual experience                                                           

   Yes                                   210 (96.3)             8 (3.7)                X^2^=9.786

   No                                    146 (88.0)             20 (12.0)              *P*=0.002

   Total                                 356 (92.7)             28 (7.3)               

  Number of sexual partners                                                            

   \<3                                   342 (93.4)             24 (6.6)               X^2^=9.627

   4-6                                   6 (66.7)               3 (33.3)               *P*=0.008

   7-9                                   2 (100.0)              0 (0.0)                

   Total                                 356 (92.7)             28 (7.3)               

  Use of condom                                                                        

   Yes                                   158 (98.1)             3 (1.9)                X^2^=12.085

   No                                    198 (88.8)             25 (11.2)              *P*=0.001

   Total                                 356 (92.7)             28 (7.3)               
  ------------------------------------------------------------------------------------------------------------

Discussion {#sec1-4}
==========

About half (47.4%) of the respondents were between the ages of 21.3 ± 2.0 years with a mean age of 21.3 ± 2.0. Majority (70%) were from Yoruba ethnic group, and about 60% were Christians. This can be attributed to the fact that this study was conducted in Lagos state which is one of the six Yoruba speaking states of south west Nigeria. Over 98% of them own a mobile phone while about 95% have access to the use of internet. This shows the students are functioning within the current global trends.

Respondent\'s knowledge about HPV in this study was very low. About 97.0% had poor knowledge regarding HPV and HPV vaccine. This finding is similar to that of a study conducted among female adolescents in Ibadan South west, Nigeria, which reported that knowledge of HPV vaccine was generally poor and that only 11.8% of the respondents had good knowledge.\[[@ref17]\] This result is lower compared to that of a study conducted among medical and dental students in a tertiary institution in Benin, Nigeria, which reported that 31.2% had good knowledge about HPV infection and vaccination.\[[@ref16]\] The reason for a relatively higher knowledge among medical students may be attributed to the fact that the respondents were medical students who might have had lectures on HPV.

More than half (54.4%) of the respondents in this study did not know that HPV vaccine prevents cervical cancer, genital warts and oral cancers. The finding is similar to that of a study conducted among female students in the university of Lagos Nigeria, where about 62% of the respondents did not know that HPV infection can cause cervical cancer.\[[@ref20]\] More than half (58%) of the respondents in our study did not know that HPV can be transmitted through sexual contact while about two-third (63%) did not know that having multiple partners increases the risk of HPV infection which causes cervical cancer. The low level of knowledge found in this study may be related to the little coverage that is given to HPV and sex education programs in Nigeria. It has been observed from literatures that students studying in programs unrelated to medical/health care have less knowledge compared to those in medical related disciplines.\[[@ref16][@ref21][@ref22]\]

Despite the poor knowledge of HPV and its vaccine among the respondents, majority of them (93%) had positive attitude towards uptake of HPV vaccine. This finding is similar to studies among mothers of adolescent in Nigeria, where 73.5% had positive attitude towards the uptake of HPV vaccine for their daughters and another study conducted among Ghanaian women which reported that 94% of the respondents were willing to vaccinate themselves or their daughters.\[[@ref23][@ref24]\] High acceptance of HPV vaccination or high interest in obtaining HPV vaccines has been reported in recent studies in Italy and Honduras with \>70% willingness of the majority of the adolescents and young women to recommend the vaccine to others or to accept it for themselves.\[[@ref25][@ref26]\] A study done among students in Berlin, Germany reported that 79% of the respondents had positive attitude to the uptake of HPV vaccine.\[[@ref27]\] A systematic review in developing countries of South-East Asia Region reported the percentage of knowledge of availability of HPV vaccine to be varied from 7.8-97.5%, while the positive attitude ranged from 36.1-92.1%.\[[@ref28]\]

In this present study, only ten (2.6%) of the respondents have been vaccinated with HPV vaccine which corroborates a similar finding from a study conducted among female students in Benin, Nigeria, where about 3.7% of the respondents have received HPV vaccine, and another study done among female adolescents in Ibadan, where only about 4.1% had received the vaccine.\[[@ref16][@ref17]\] Likewise, a study conducted among female medical students in a tertiary institute in India reported that only 6.8% of the respondents had received HPV vaccination.\[[@ref22]\] The reason for low uptake found in this study may be due to the fact that Nigerian government is yet to organize a subsidized vaccination program for HPV. On the contrary, similar studies conducted in some developed countries like Germany and the United states reported a considerable high uptake of HPV vaccines of 53% and 62.4% respectively.\[[@ref29][@ref30]\] The higher uptake of HPV vaccine seen in developed countries could be attributed to vaccination subsidy in such countries. In order to increase the HPV vaccination rate in Nigeria, the government may need to consider subsidizing the cost.

The four most common reasons or barriers for non-vaccination with HPV vaccine as reported by the respondents were as follows: insufficient information about the vaccine, safety concerns, expensive cost, and the fact that they don't know where to get the vaccine. The reasons for none uptake of the vaccine (safety concerns and high cost) is similar to that reported by a study conducted among HIV positive women in Nigeria who stated safety concerns (24.4%) and expensive cost of the vaccine (19.5%) as the reasons for failure of uptake of HPV vaccine.\[[@ref31]\] Another study among adolescents in Nigeria reported that 62% of the respondents stated expensive cost for non-uptake of HPV vaccine.\[[@ref23]\] Similarly, a study among mothers of adolescents in Lagos state found that most (96.5%) of the respondents reported that they would want more information on HPV and its vaccine which corroborates a similar barrier in this study which reported respondents need for more information.\[[@ref32]\] More so, a study done among female Iranian nurses reported that inadequate knowledge of HPV vaccine (26.2%) and safety concerns (41.4%) were the major reasons for unwillingness to be vaccinated,\[[@ref33]\] which is consistent with findings in this study where respondents stated the need for more information before becoming vaccinated and safety concerns as barriers to vaccination. Generally, studies have reported the most common barriers to uptake of HPV vaccination were mostly insufficient information about and high cost of the vaccine.\[[@ref23][@ref31][@ref32][@ref33]\] These barriers can be overcome by target interventions aimed at increasing knowledge of HPV vaccine among young persons and vaccination subsidization in Nigeria.

Statistically significant associations were found between age, level of study, course of study of the respondents and knowledge of HPV and its vaccine (*P* ≤ 0.05). This finding is similar to that of a study conducted among female Medical and Dental students in a tertiary institution in Benin-city, Nigeria where age (*P* = 0.001), faculty (*P* = 0.014), level of study (*P* = 0.001) were significantly associated with knowledge of HPV.\[[@ref16]\] Another study conducted among medical and para-medical students in India showed a statistically significant association between level of study of respondents and knowledge of HPV vaccine (*P* \< 0.001), with increasing seniority in classes, the odds of good knowledge about HPV vaccination increased.\[[@ref22]\] This implies that the higher the level, the better the knowledge of HPV and vaccine. In this study, there was a statistically significant association between age of the respondents (*P* = 0.034), previous sexual experience (*P* = 0.002), number of sexual partners (*P* = 0.008) and respondents' attitude towards HPV vaccine. This finding however is contrary to that of some other studies which showed no significant association between sociodemographic variables and attitude of respondents towards HPV vaccine.\[[@ref16][@ref17][@ref23][@ref32]\] This study also found a significant association between respondent\'s knowledge of HPV vaccine and the willingness to be vaccinated (*P* = 0.002), which is in accordance with other studies conducted in India and Ibadan, (*P* \< 0.001) and (*P* = 0.007) respectively.\[[@ref17][@ref22]\] This implies that respondents with good knowledge of HPV and its vaccine were more willing and ready to be vaccinated compared to those with poor knowledge.

Limitation of the study {#sec2-11}
-----------------------

There was a possibility for recall bias since data since this was a cross-sectional survey design. Another potential limitation that should be considered when interpreting this study is that the information obtained was collected using a self-administered questionnaire and so the possibility exists that some of the respondents may not have answered some of the questions correctly.

Conclusion {#sec1-5}
==========

The respondent\'s knowledge of HPV and its vaccine was generally poor and the uptake of HPV vaccine was very low. However, there was a predominantly positive attitude towards uptake of HPV vaccine. Therefore, health education programs focused on increasing awareness and knowledge of HPV vaccine among female undergraduates in Lagos State Institutions is highly recommended. Also, the government should endeavor to include HPV vaccine in the National Program on Immunization (NPI) schedule for easy accessibility.
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